Ronald A. Andrews
Chief Business Officer & DirectorMr. Ronald A. Andrews, Jr. also known as Ronnie, Ron, was Independent Director of Cerenome, Inc. (formerly known as Plus Therapeutics, Inc.) from March 2026 to November 9, 2026 and is its Chief Business Officer & Director since November 9, 2026. He is responsible for advancing enterprise growth strategy, strategic partnerships, corporate development and business opportunities across the Company's diagnostics, therapeutics and data analytics platforms. He serves as Director of Agendia, Inc. since June 2023. He had been Chief Executive Officer and Director of TwinStrand Biosciences, Inc. since July 2023 until September 2026. Mr. Andrews has served as the Executive Chairman of SimBioSys, Inc, a private Chicago based AI company, since fall of 2022. He served as Interim Chief Executive Officer at TwinStrand Biosciences, Inc. since May 2023 until July 2023. He has been an Independent Director of Precipio, Inc. since March 01, 2021. Mr. Andrews serves as Supervisory Board Member of Agendia N.V. He had been the Chief Executive Officer of OncoCyte Corporation since July 1, 2019 until December 01, 2022 and served as its Director since April 2018 until December 01, 2022. Mr. Andrews served as President at OncoCyte Corporation since July 1, 2019. Mr. Andrews had been an Independent Non-Executive Director of Oxford Immunotec Global PLC since November 4, 2015 until March 08, 2021 and Insight Genetics, Inc. since November 10, 2015. He was Chief Commercial Officer at Roche Molecular. Mr. Andrews is the Founder and Principal of The Bethesda Group. He served as the President of Genetic, Medical and Applied Sciences at Life Technologies Corporation since June 26, 2013 until February 2015. Mr. Andrews was responsible for leading Life Technologies Corporation's Ion Torrent, genetic analysis and medical sciences businesses using his deep molecular diagnostic experience in instrument systems development and commercialization, as well as the clinical application of molecular technologies, to align these businesses around a common vision as expands its business toward the clinic. He is an executive with experience in the US Clinical & Molecular Diagnostics and genomics industries. His main focus is leading the transition of the molecular discoveries from the life science research area into molecular diagnostic applications to improve patient care. Mr. Andrews has an experience in the diagnostics industry. He served as the President of the Genetic Sciences Division for Thermo Fisher Scientific from September 2013 to December 2014. He served as Chief Executive Officer and President of Clarient, Inc. from July 22, 2004 until 2012 and from July 22, 2004 to April 2008 respectively. He served as President of Medical Sciences of Life Technologies Corporation since February 2, 2012 until September 2013. From December 2010 to February 2012 he served as Chief Executive Officer of GE Molecular Diagnostics after Clarient was acquired by GE Healthcare. Mr. Andrews served as Segment Leader of GE Molecular Diagnostics at Clarient Inc. from 2004 until 2012 and led integration of Clarient, maintaining the annual growth and establishing a strategic plan to expand GE's presence in oncology diagnostics. While at Clarient, he transformed ChromaVision Medical Systems from a device manufacturer to a comprehensive cancer diagnostics company. From August 2002, Mr. Andrews also served at Roche Molecular Diagnostics as Senior Vice President of Global Marketing and Commercial Business Operations. He developed and led the strategic execution for all diagnostic commercial operations. This included the oversight of five business sector Vice President responsible for all aspects of global marketing and business development in the areas of blood screening, virology, women’s health, microbiology and automation/emerging diagnostics. Mr. Andrews was also responsible for executive direction of all marketing functions, directed the development of the Strategic Plan and completed the reorganization of commercial operations during that period. From 2000 to 2002, Mr. Andrews held two senior executive positions with Roche Diagnostics Corporation. As Vice President of United States Commercial Operations, Molecular Diagnostics, he directed sales, marketing, technical field support and product development activities and was responsible for United States commercial strategy development for the clinical laboratory market. He served as the Vice President of Marketing, United States, Commercial Operations, he was responsible for planning and directing all aspects of the Roche United States Laboratory Systems Commercial Operations Marketing which included the clinical chemistry, immunochemistry, hematology, near patient testing and molecular markets. From 1995 to 2000, Mr. Andrews served Vice President of Immucor, Inc. where he helped lead the transition of it from a reagent manufacturer to an instrument systems company. He spent his Career working in management positions of increasing responsibility at Abbott Diagnostics, culminating in the position of Senior Marketing Manager, Business Unit Operations. Mr. Andrews has held leadership positions at companies such as GE Healthcare and established a strategic plan to integrate In Vivo and In Vitro and expand GE’s presence in oncology. He served as Vice Chairman of Clarient, Inc since April 28, 2008 until December 2010. He served as an Independent Director of Orion Health Group Limited/Orion Healthcare since September 1, 2016 until 2019. Mr. Andrews is also a Member of the Board of Governors of CancerLinQ LLC, a wholly-owned non-profit subsidiary of the American Society of Clinical Oncology. He serves as Member of Scientific Advisory Board at BioTrove, Inc. Mr. Andrews serves as Member of Advisory Board at Enerliance, Inc. He served as Member of Advisory Board and served on Life Sciences Advisory Board at Safeguard Scientifics, Inc. He served as Director of Clarient, Inc. since July 22, 2004. He served as Director of Cardiac Science Corporation from November 5, 2009 to December 1, 2010. He served as Member of Scientific Advisory Board at Definiens AG until September 15, 2015. He applies his expertise to expand Life Technologies' presence in the diagnostics and personalized medicine space through strategies including short and long term Partnerships. He has participated extensively in the executive development programs at both Roche and Abbott Labs. Mr. Andrews has earned a B.S. in Biology and Chemistry from Spartanburg, South Carolina based Wofford College in 1977 to 1981.
Positions
- Company NameCerenome, Inc.Stock CodeCNSYPositionChief Business Officer & DirectorColleagues
- MHMarc H. HedrickPresident, CEO & Director
- RJRichard J. HawkinsIndependent Chairman of the Board
- AJAndrew J. SimsVP & CFO
- EJEric J. DanielsChief Development Officer & COO
- RHRuss HavranekExecutive Vice President of Commercial and Corporate Strategy
- AVAn van Es-JohanssonIndependent Director
- HCHoward ClowesIndependent Director
